VEGF regulates antidepressant effects of lamotrigine

European Neuropsychopharmacology

Volumn 22, Issue 6, 2012, Pages 424-430

  Sun, Rongju ^a   Li, Nanxin ^b   Li, Tanshi ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b YALE UNIVERSITY   (United States)

Author keywords

Antidepressant; CUS; FST; Lamotrigine; NSF; VEGF

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LAMOTRIGINE; NEUROTROPHIN; SEMAXANIB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STRESS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; FOOD PREFERENCES; FRONTAL LOBE; HIPPOCAMPUS; INDOLES; MALE; PROTEIN KINASE INHIBITORS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL; SUCROSE; SWEETENING AGENTS; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860443838     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.09.010     Document Type: Article

References (29)

1. Ali A., Pillai K.K., Pal S.N. Effects of folic acid and lamotrigine therapy in some rodent models of epilepsy and behaviour. J. Pharm. Pharmacol. 2003, 55:387-391.
2. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
3. Bourin M., Prica C. The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders. Neurosci. Biobehav. Rev. 2007, 31:963-975.
4. Bourin M., Masse F., Hascoet M. Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J. Psychiatry Neurosci. 2005, 30:275-282.
5. Bowden C.L., Mitchell P., Suppes T. Lamotrigine in the treatment of bipolar depression. Eur. Neuropsychopharmacol. 1999, 9(Suppl. 4):S113-S117.
6. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 study group. J. Clin. Psychiatry 1999, 60:79-88.
7. Calabrese J.R., Shelton M.D., Rapport D.J., Kujawa M., Kimmel S.E., Caban S. Current research on rapid cycling bipolar disorder and its treatment. J. Affect. Disord. 2001, 67:241-255.
8. Chang Y.C., Rapoport S.I., Rao J.S. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem. Res. 2009, 34:536-541.
9. Consoni F.T., Vital M.A., Andreatini R. Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. Eur. Neuropsychopharmacol. 2006, 16:451-458.
10. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004, 5:11-25.
11. Einat H., Manji H.K., Gould T.D., Du J., Chen G. Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News Perspect. 2003, 16:453-463.
12. Greene J., Banasr M., Lee B., Warner-Schmidt J., Duman R.S. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009, 34:2459-2468.
13. Heine V.M., Zareno J., Maslam S., Joels M., Lucassen P.J. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur. J. Neurosci. 2005, 21:1304-1314.
14. Howell K.R., Kutiyanawalla A., Pillai A. Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex. PLoS One 2011, 6:e20198.
15. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., Greenberg D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11946-11950.
16. Li N., He X., Qi X., Zhang Y., He S. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor. J. Psychopharmacol. 2010, 23:1772-1778.
17. Li N., He X., Zhang Y., Qi X., Li H., Zhu X., He S. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine. Int. J. Neuropsychopharmacol. 2011, 1-8.
18. McCloskey D.P., Croll S.D., Scharfman H.E. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J. Neurosci. 2005, 25:8889-8897.
19. Newton S.S., Collier E.F., Hunsberger J., Adams D., Terwilliger R., Selvanayagam E., Duman R.S. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J. Neurosci. 2003, 23:10841-10851.
20. Pilar-Cuellar F., Vidal R., Pazos A. Subchronic treatment with fluoxetine and the 5-HT(2A) antagonist ketanserin upregulates hippocampal BDNF and beta-catenin in parallel with antidepressant-like effect. Br. J. Pharmacol. 2011, doi:10.1111/j.1476-5381.2011.01516.x (Electronic publication ahead of print).
21. Prica C., Hascoet M., Bourin M. Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. Behav. Brain Res. 2008, 191:49-54.
22. Rao J.S., Rapoport S.I. Mood-stabilizers target the brain arachidonic acid cascade. Curr. Mol. Pharmacol. 2009, 2:207-214.
23. Schanzer A., Wachs F.P., Wilhelm D., Acker T., Cooper-Kuhn C., Beck H., Winkler J., Aigner L., Plate K.H., Kuhn H.G. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol. 2004, 14:237-248.
24. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol. 2007, 18:391-418.
25. Segi-Nishida E., Warner-Schmidt J.L., Duman R.S. Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11352-11357.
26. Storkebaum E., Lambrechts D., Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004, 26:943-954.
27. Warner-Schmidt J.L., Duman R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4647-4652.
28. Warner-Schmidt J.L., Duman R.S. VEGF as a potential target for therapeutic intervention in depression. Curr. Opin. Pharmacol. 2008, 8:14-19.
29. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.